Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan

International Journal of Clinical Practice

Volumn 63, Issue 10, 2009, Pages 1446-1450

  Devendra, D ^a,b,c   Gohel, B ^c   Bravis, V ^b   Hui, E ^c   Salih, S ^a   Mehar, S ^a   Hassanein, M ^d  

^a NHS Brent   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^d GLAN CLWYD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIET RESTRICTION; DRUG DOSE INCREASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOSLEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT EDUCATION; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; WEIGHT CHANGE; WEIGHT GAIN; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; ETHNOLOGY; ISLAM; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLAM; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; TREATMENT OUTCOME;

EID: 70349245219     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02171.x     Document Type: Article

References (14)

1. Rashed AH. The fast of Ramadan. BMJ 1992 304 : 521 522.
2. Salti I, Bénard E, Detournay B et al. Results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004 27 : 2306 2311.
3. Al-Arouj M, Bouguerra R, Buse J et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005 28 : 2305 2311.
4. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes. Diabet Med 2008 25 : 245 254.
5. Alvarez Guisasola F, Tofé Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with Type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008 10 (Suppl. 1 25 32.
6. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005 28 : 2948 2961.
7. Watkins PJ. ABC of Diabetes, 5th edn. London : BMJ Books, 2002.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
9. Ahrén B, Foley JE. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism. Int J Clin Pract 2008 62 (Suppl. 159 8 14.
10. Garber AJ, Sharma MD. Update: vildagliptin for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2008 17 : 105 113.
11. Ferrannini E, Fonseca V, Zinman B et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009 11 : 157 166.
12. Dunning BE, Foley JE, Ahren B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia 2005 48 : 1700 1713.
13. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009 11 : 506 515.
14. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. European implications of the READ (Ramadan focused Education and Awareness in Diabetes) programme [Abstract]. Diabetologia 2008 51 (Suppl. S454.